Your browser is no longer supported. Please, upgrade your browser.
AgeX Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.29 Insider Own0.10% Shs Outstand37.69M Perf Week-5.11%
Market Cap49.32M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float21.21M Perf Month-20.25%
Income-10.90M PEG- EPS next Q- Inst Own17.80% Short Float2.84% Perf Quarter-51.49%
Sales1.90M P/S25.96 EPS this Y11.60% Inst Trans0.49% Short Ratio2.33 Perf Half Y-20.25%
Book/sh-0.14 P/B- EPS next Y- ROA-241.80% Target Price- Perf Year71.96%
Cash/sh0.01 P/C98.64 EPS next 5Y- ROE363.70% 52W Range0.67 - 3.93 Perf YTD-14.47%
Dividend- P/FCF- EPS past 5Y- ROI-876.80% 52W High-68.19% Beta-
Dividend %- Quick Ratio0.40 Sales past 5Y- Gross Margin91.50% 52W Low86.57% ATR0.09
Employees6 Current Ratio0.40 Sales Q/Q0.00% Oper. Margin- RSI (14)29.61 Volatility4.44% 6.52%
OptionableNo Debt/Eq- EPS Q/Q9.90% Profit Margin- Rel Volume0.31 Prev Close1.30
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume257.86K Price1.25
Recom- SMA20-11.57% SMA50-26.35% SMA200-20.56% Volume79,287 Change-3.85%
Mar-31-21 04:05PM  
Mar-12-21 08:00AM  
Mar-10-21 08:00AM  
Mar-02-21 08:00AM  
Feb-02-21 11:24PM  
Dec-22-20 03:08PM  
Nov-27-20 04:13PM  
Nov-16-20 04:05PM  
Oct-28-20 08:00AM  
Sep-15-20 07:59AM  
Sep-09-20 08:00AM  
Aug-14-20 04:05PM  
Aug-07-20 07:02AM  
Jun-16-20 08:00AM  
Jun-05-20 04:15PM  
Jun-02-20 08:00AM  
May-29-20 08:00AM  
May-21-20 08:30AM  
May-14-20 04:05PM  
May-01-20 08:54AM  
Mar-30-20 05:40PM  
Mar-20-20 09:00AM  
Feb-28-20 08:00AM  
Feb-09-20 09:12AM  
Feb-03-20 08:00AM  
Jan-29-20 08:00AM  
Jan-14-20 08:00AM  
Dec-26-19 08:00AM  
Dec-10-19 08:00AM  
Dec-09-19 07:00AM  
Nov-14-19 04:00PM  
Nov-13-19 09:50AM  
Nov-11-19 05:28AM  
Nov-08-19 06:58PM  
Oct-30-19 08:00AM  
Oct-11-19 08:00AM  
Sep-10-19 08:00AM  
Sep-09-19 07:00AM  
Sep-04-19 08:00AM  
Aug-14-19 05:16PM  
Aug-05-19 05:14PM  
Jul-09-19 08:00AM  
May-15-19 04:05PM  
May-01-19 08:00AM  
Apr-05-19 08:00AM  
Apr-01-19 04:48PM  
Mar-22-19 07:00AM  
Mar-21-19 07:00AM  
Mar-07-19 07:00AM  
Feb-14-19 08:00AM  
Jan-31-19 08:00AM  
Jan-22-19 08:00AM  
Jan-10-19 08:00AM  
Jan-09-19 08:00AM  
Jan-04-19 08:00AM  
Jan-02-19 07:00AM  
AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as the ischemic heart. Its lead drug-based therapeutic candidate in discovery is AGEX-iTR1547, a drug-based formulation to restore regenerative potential in a range of aged tissues afflicted with degenerative diseases. In addition, the company markets human embryonic stem cells; and GeneCards Database Suite, including genomic interpretation algorithms and analysis tools for use by researchers at pharmaceutical and biotechnology companies, and other institutions. AgeX Therapeutics, Inc. has a research collaboration with the University of California, Irvine on neural stem cell research program for Huntington's disease and other neurological disorders; a collaboration with Sernova Corp.; and a research collaboration with The Ohio State University using AgeX's brown adipocyte tissue cell therapy candidate AgeX-BAT1 in mice to determine whether transplantation of AgeX-BAT1 cells may improve diet-induced obesity, metabolic health, and cardiac function. The company was founded in 2017 and is based in Alameda, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
WEST MICHAEL DChief Executive OfficerMar 11Option Exercise0.003,125033,723Mar 15 09:35 PM
WEST MICHAEL DChief Executive OfficerDec 11Option Exercise0.003,125031,679Dec 15 09:33 PM
WEST MICHAEL DChief Executive OfficerSep 11Option Exercise0.003,125029,635Sep 15 09:37 PM
WEST MICHAEL DChief Executive OfficerJun 11Option Exercise0.003,125027,591Jun 15 09:29 PM